Shares of Gentium SpA (Nasdaq:GENT) have taken a tremendous swing upward. The stock is trading at $7.01 as of 2:54 p.m. ET, 22.6% above Tuesday's closing price of $5.72. Volume is at 371,527, 14.9 times the daily average of 25,000.
NEW YORK ( TheStreet) -- Shares of Gentium SpA (Nasdaq: GENT) have taken a tremendous swing upward. The stock is trading at $7.01 as of 2:54 p.m. ET, 22.6% above Tuesday's closing price of $5.72. Volume is at 371,527, 14.9 times the daily average of 25,000. Gentium SpA has a market cap of $84 million and is part of the health care sector and drugs industry. Shares are down 7.7% year to date as of the close of trading on Tuesday. Gentium S.p.A., a biopharmaceutical company, focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. The company has a P/E ratio of 14.8, below the average drugs industry P/E ratio of 19.6 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Gentium SpA as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full Gentium SpA Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.